Skip to contentS
Sanara MedTech Inc.
S
SMTISanara MedTech Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$15.32M$15.32Mderived+117.8% vs Q4 2021 Net Income-$4.11M-$4.11MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sanara MedTech Inc. · CIK 714256 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$12,947,150+107.1% Operating Incomederived-$3,123,174N/M Operating Cash Flowderived-$645,016N/M Free Cash Flowderived-$698,380N/M Margins · derivedGross margin84.5%−4.3 pt vs Q4 2021
Operating margin-20.4%+28.1 pt vs Q4 2021
Net margin-26.8%+22.7 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 20, 2023 · 79 d after period end